| 8.76 -0.26 (-2.88%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.8 |
1-year : | 12.91 |
| Resists | First : | 10.1 |
Second : | 11.06 |
| Pivot price | 9.47 |
|||
| Supports | First : | 8.56 |
Second : | 7.13 |
| MAs | MA(5) : | 9.01 |
MA(20) : | 9.71 |
| MA(100) : | 10.57 |
MA(250) : | 12.59 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.6 |
D(3) : | 11.3 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 18.56 | Low : | 7.48 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BHVN ] has closed above bottom band by 4.3%. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.99 - 9.06 | 9.06 - 9.11 |
| Low: | 8.42 - 8.5 | 8.5 - 8.55 |
| Close: | 8.66 - 8.78 | 8.78 - 8.86 |
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Fri, 15 May 2026
[SCHEDULE 13G/A] Biohaven Ltd. Amended Passive Investment Disclosure - Stock Titan
Fri, 15 May 2026
BHVN Stock Price Prediction 2025-2026 | Biohaven Pharmaceutical Holding Co Ltd Forecast - 24/7 Wall St.
Thu, 14 May 2026
Biohaven Ltd. (BHVN) Receives a Hold from Bernstein - The Globe and Mail
Thu, 14 May 2026
BHVN Technical Analysis | Trend, Signals & Chart Patterns | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Wed, 13 May 2026
BHVN Stock Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Wed, 13 May 2026
Biohaven Ltd. Stock 12‑Month Price Target Cut to $22.19, Implies 141% Upside - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 150 (M) |
| Shares Float | 124 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 91.7 (%) |
| Shares Short | 23,780 (K) |
| Shares Short P.Month | 21,900 (K) |
| EPS | -6.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -83.1 % |
| Return on Equity (ttm) | -310.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -609 (M) |
| Levered Free Cash Flow | -358 (M) |
| PE Ratio | -1.28 |
| PEG Ratio | 0 |
| Price to Book value | 22.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|